Pharmaceuticals, Biotechnology & Life Sciences

Insider selling at ANI: Cook Meredith’s structured 500‑share July sale shows routine trading, not panic—monitor Phase‑4 ILUVIEN results for future upside.

Insider buying at Agenus (AGUS) shows strong confidence amid a 45% weekly rally, new Phase 3 ROBBIN trial, and $340 M private placement—an insider‑backed catalyst for investors.

Oruka Insider Trading Insight: Arjun’s Rule 10b5‑1 moves mix strategic liquidity with long‑term confidence, revealing a disciplined approach to the biotech’s growth.

BridgeBio insiders buy low & sell high, signaling confidence in the gene‑editing pipeline and a potential rally ahead of key clinical data.

Discover why C4 Therapeutics’ chief medical officer is buying shares at zero cost after RSU vesting—insider confidence signals a biotech upside worth watching.

Indivior insider sale by CSO Christian Heidbreder shows routine 10‑b‑5 trading amid a 161% YTD rally, confirming confidence in future clinical gains.

MoonLake CEO’s planned July 9th sale of 33,936 shares at $20.01 signals disciplined portfolio management, not panic, amid rising clinical prospects.

Insight into TWST insider activity: CFO sells 2,399 shares at $94.33—routine, routine‑level liquidity moves, not a warning for investors.

RIGEL Pharma insider buys 24,400 shares, boosting confidence as stock climbs near 52‑week highs and social buzz spikes—investors note strong momentum.

Insider option grants at Cellectar Biosciences signal executive confidence and a bullish outlook for the drug‑development biotech, despite a volatile stock.